Abstract
ONO-1714 is a newly developed specific inhibitor for inducible nitric oxide synthase (iNOS). We have shown that ONO-1714 has some neuroprotective effects. In this report, we investigated the effects of ONO-1714 in injured spinal cords, and analyzed the expression of glial cell-line-derived neurotrophic factor (GDNF) after injury. Male Sprague-Dawley rats were subjected to contusive spinal cord injury and administrated 0.1 mg/kg ONO-1714. The injured spinal cords were isolated at appropriate time points and GDNF mRNA was determined by semi-quantitative RT-PCR. GDNF-positive cells were also counted after immunohistochemical stainings. ONO-1714 diminished the early stage production of GDNF after injury as well as it reduced the production of nitric oxide produced by iNOS and apoptotic cells.
MeSH terms
-
Amidines / therapeutic use*
-
Animals
-
DNA Primers
-
Disease Models, Animal
-
Enzyme Inhibitors / therapeutic use
-
Glial Cell Line-Derived Neurotrophic Factor
-
Heterocyclic Compounds, 2-Ring / therapeutic use*
-
Nerve Growth Factors / antagonists & inhibitors
-
Nerve Growth Factors / genetics*
-
Nitric Oxide Synthase / antagonists & inhibitors*
-
Nitric Oxide Synthase Type II
-
Polymerase Chain Reaction
-
RNA, Messenger / genetics
-
Rats
-
Spinal Cord / pathology
-
Spinal Cord Injuries / drug therapy*
-
Spinal Cord Injuries / physiopathology*
-
Time Factors
-
Transcription, Genetic / drug effects
Substances
-
7-chloro-3-imino-5-methyl-2-azabicyclo(4.1.0)heptane
-
Amidines
-
DNA Primers
-
Enzyme Inhibitors
-
Gdnf protein, rat
-
Glial Cell Line-Derived Neurotrophic Factor
-
Heterocyclic Compounds, 2-Ring
-
Nerve Growth Factors
-
RNA, Messenger
-
Nitric Oxide Synthase
-
Nitric Oxide Synthase Type II
-
Nos2 protein, rat